A detailed history of State Street Corp transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, State Street Corp holds 87,637 shares of MLTX stock, worth $4.77 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
87,637
Previous 44,657 96.24%
Holding current value
$4.77 Million
Previous $1.96 Million 125.06%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$40.15 - $55.4 $1.73 Million - $2.38 Million
42,980 Added 96.24%
87,637 $4.42 Million
Q2 2024

Aug 14, 2024

SELL
$38.43 - $48.6 $27,054 - $34,214
-704 Reduced 1.55%
44,657 $1.96 Million
Q1 2024

May 15, 2024

BUY
$43.78 - $63.86 $657,575 - $959,177
15,020 Added 49.5%
45,361 $2.28 Million
Q4 2023

Feb 14, 2024

BUY
$36.35 - $63.02 $346,815 - $601,273
9,541 Added 45.87%
30,341 $1.83 Million
Q3 2023

Nov 14, 2023

BUY
$48.35 - $61.26 $1.01 Million - $1.27 Million
20,800 New
20,800 $1.19 Million

Others Institutions Holding MLTX

About MoonLake Immunotherapeutics


  • Ticker MLTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,925,600
  • Market Cap $2.01B
  • Description
  • MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...
More about MLTX
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.